Enadenotucirev Preclinical

Directed evolution generates a novel oncolytic virus for the treatment of colon cancer

Kuhn I, Harden P, Bauzon M, Chartier C, Nye J, Thorne S, Reid T, Ni S, Lieber A, Fisher K, Seymour L, Rubanyi GM, Harkins RN, Hermiston TW. PLoS ONE 2008; 3 (6):e2409.  

adm1nEnadenotucirev Preclinical

Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood

Di Y, Seymour L, Fisher K. Gene Therapy 2014; 21:440. 

adm1nEnadenotucirev Preclinical

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators

Dyer A, Ying D, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, et al. Mol Ther Oncolytics. 2017;4:18-30. 

Nitin JainEnadenotucirev Preclinical

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer

Chiaa SL, Leia J, Fergusonc D, Dyera A, Fisher K, Seymour L.  Virology 505 (2017) 162–171

Nitin JainEnadenotucirev Preclinical

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Fisher K. Mol Ther Oncolytics. 2017;5:62-74

Nitin JainEnadenotucirev Preclinical
Back to Top
Responsive Menu Pro Image Responsive Menu Clicked Image
Menu